Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up

References

1. 1.↵
   2. Ohgaki H.

   Epidemiology of brain tumors. Methods Mol Biol. 2009; 472: 323–42.

   OpenUrlCrossRefPubMed
2. 2.
   2. Rasmussen BK,
   3. Hansen S,
   4. Laursen RJ,
   5. Kosteljanetz M,
   6. Schultz H,
   7. Norgard BM, et al.

   Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the Danish Neuro-Oncology Registry. J Neurooncol. 2017; 135: 571–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   2. Diwanji TP,
   3. Engelman A,
   4. Snider JW,
   5. Mohindra P.

   Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther. 2017; 8: 99–113.

   OpenUrlCrossRefPubMed
4. 4.↵
   2. Gallego O.

   Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2015; 22: e273–81.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Li SY,
   3. Chang CQ,
   4. Ma FY,
   5. Yu CL.

   Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet. Biomed Environ Sci. 2009; 22: 122–9.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Xu R,
   3. Kang Q,
   4. Ren J,
   5. Li Z,
   6. Xu X.

   Antitumor molecular mechanism of chlorogenic acid on inducting genes GSK-3β and APC and inhibiting gene β-Catenin. J Anal Methods Chem. 2013; 2013: 951319.
7. 7.
   2. Bandyopadhyay G,
   3. Biswas T,
   4. Roy KC,
   5. Mandal S,
   6. Mandal C,
   7. Pal BC, et al.

   Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood. 2004; 104: 2514–22.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   2. Xue N,
   3. Zhou Q,
   4. Ji M,
   5. Jin J,
   6. Lai F,
   7. Chen J, et al.

   Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep. 2017; 7: 39011.
9. 9.↵
   2. Jin UH,
   3. Lee JY,
   4. Kang SK,
   5. Kim JK,
   6. Park WH,
   7. Kim JG, et al.

   A phenolic compound, 5-caffeoylquinic acid (chlorogenic acid), is a new type and strong matrix metalloproteinase-9 inhibitor: isolation and identification from methanol extract of Euonymus alatus. Life Sci. 2005; 77: 2760–9.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    2. Wu J,
    3. Chen H,
    4. Li H,
    5. Tang Y,
    6. Yang L,
    7. Cao S, et al.

    Antidepressant potential of chlorogenic acid-enriched extract from Eucommia ulmoides Oliver Bark with neuron protection and promotion of serotonin release through enhancing synapsin I expression. Molecules. 2016; 21: 260.

    OpenUrl
11. 11.↵
    2. Wen PY,
    3. Macdonald DR,
    4. Reardon DA,
    5. Cloughesy TF,
    6. Sorensen AG,
    7. Galanis E, et al.

    Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963–72.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Galanis E,
    3. Jaeckle KA,
    4. Maurer MJ,
    5. Reid JM,
    6. Ames MM,
    7. Hardwick JS, et al.

    Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009; 27: 2052–8.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    2. van Linde ME,
    3. Brahm CG,
    4. de Witt Hamer PC,
    5. Reijneveld JC,
    6. Bruynzeel AME,
    7. Vandertop WP, et al.

    Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. J Neurooncol. 2017; 135: 183–92.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Wu HZ,
    3. Luo J,
    4. Yin YX,
    5. Wei Q.

    Effects of chlorogenic acid, an active compound activating calcineurin, purified from Flos Lonicerae on macrophage. Acta Pharmacol Sin. 2004; 25: 1685–9.

    OpenUrlPubMed
15. 15.↵
    2. Park JJ,
    3. Hwang SJ,
    4. Park JH,
    5. Lee HJ.

    Chlorogenic acid inhibits hypoxia-induced angiogenesis via down-regulation of the HIF-1alpha/AKT pathway. Cell Oncol (Dordr). 2015; 38: 111–8.

    OpenUrl
16. 16.↵
    2. Wick A,
    3. Pascher C,
    4. Wick W,
    5. Jauch T,
    6. Weller M,
    7. Bogdahn U, et al.

    Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol. 2009; 256: 734–41.

    OpenUrlCrossRefPubMedWeb of Science